<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04733742</url>
  </required_header>
  <id_info>
    <org_study_id>BRIDGE-TNK</org_study_id>
    <nct_id>NCT04733742</nct_id>
  </id_info>
  <brief_title>Endovascular Treatment With Versus Without Intravenous Tenecteplase in Stroke</brief_title>
  <acronym>BRIDGE-TNK</acronym>
  <official_title>Intravenous Tenecteplase Bridging With Endovascular Treatment Versus Endovascular Treatment Alone For Stroke Patient With Large Vessel Occlusion: A Multicenter, Double-Blind, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wuhan No. 1 Hospital (Wenhua Liu)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The 904th Hospital of PLA (Zhonghua Shi)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Jilin University (Shouchun Wang)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maoming Traditional Chinese Medicine Hospital (Wenguo Huang)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xinqiao Hospital of Chongqing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to investigate whether intravenous tenecteplase prior to&#xD;
      endovascular treatment can improve 90-day functional outcome of stroke patients with large&#xD;
      vessel occlusion who are thrombolysis-eligible within 4.5 hours of symptom onset.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The DEVT, SKIP and DIRECT-MT trials showed that endovascular treatment alone is not inferior&#xD;
      to intravenous alteplase bridging with endovascular treatment in terms of achieving 90-day&#xD;
      functional independence for stroke patients with large vessel occlusion. The EXTEND-IA TNK&#xD;
      part 1 and part 2 demonstrated that intravenous thrombolysis with tenecteplase is superior to&#xD;
      alteplase before endovascular treatment. However, it is unclear whether intravenous&#xD;
      tenecteplase bridging with endovascular treatment is superior to endovascular treatment&#xD;
      alone. The purpose of this trial is to investigate whether intravenous tenecteplase bridging&#xD;
      with endovascular treatment is better than endovascular treatment alone for stroke patients&#xD;
      with large vessel occlusion who are thrombolysis-eligible within 4.5 hours of onset.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2025</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>modified Rankin scale score</measure>
    <time_frame>90 days</time_frame>
    <description>disability level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients non-disabled (mRS score 0 to 1) or return to pre-morbid mRS score at 90 days (for patients with mRS &gt; 1)</measure>
    <time_frame>90 days</time_frame>
    <description>excellent outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients functionally independent (mRS score 0 to 2) at 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>functional independence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients ambulatory or bodily needs-capable or better (mRS score 0 to 3)</measure>
    <time_frame>90 days</time_frame>
    <description>ambulatory or bodily needs-capable or better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substantial reperfusion at initial angiogram</measure>
    <time_frame>within 5 minutes at initial angiogram</time_frame>
    <description>evaluate effect of tenecteplase on reperfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revascularization rates at 48 hours from randomization</measure>
    <time_frame>at 48 hours from randomization</time_frame>
    <description>evaluate vascular patency after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early neurologic improvement</measure>
    <time_frame>72 hours</time_frame>
    <description>Early neurologic improvement was defined as a reduction of 8 points in the NIHSS score between baseline and 72 hours or as a score of 0 or 1 at 72 hours. An 8-point reduction is considered to be highly clinically significant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life, assessed with the European Quality Five Dimensions Five Level scale (EQ-5D-5L)</measure>
    <time_frame>90 days</time_frame>
    <description>Health-related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic/Asymptomatic intracranial hemorrhage within 48 hours</measure>
    <time_frame>within 48 hours after endovascular treatment</time_frame>
    <description>evaluate intracranial hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality within 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>evaluate death rate of the two treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parenchymal hematoma</measure>
    <time_frame>within 48 hours after endovascular treatment</time_frame>
    <description>evaluate intracranial hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural-related complications and severe adverse events</measure>
    <time_frame>within 90 days</time_frame>
    <description>evaluate complications and any adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">586</enrollment>
  <condition>Stroke, Acute</condition>
  <condition>Stroke, Ischemic</condition>
  <arm_group>
    <arm_group_label>Conbined treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravenous tenecteplase bridging with endovascular treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endovascular treatment alone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>endovascular treatment alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenecteplase</intervention_name>
    <description>intravenous thrombolysis with tenecteplase followed by endovascular treatment</description>
    <arm_group_label>Conbined treatment group</arm_group_label>
    <other_name>TNKase</other_name>
    <other_name>Metalyse</other_name>
    <other_name>TNK-tPA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Endovascular treatment</intervention_name>
    <description>endovascular treatment</description>
    <arm_group_label>Conbined treatment group</arm_group_label>
    <arm_group_label>Endovascular treatment alone group</arm_group_label>
    <other_name>intra-arterial treatment</other_name>
    <other_name>interventional therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18 years or older;&#xD;
&#xD;
          2. Acute ischemic stroke confirmed by clinical symptoms or imaging examination;&#xD;
&#xD;
          3. MCA-M1 or -M2, basilar artery, or posterior cerebral artery-P1 occlusion proved by&#xD;
             CTA/MRA;&#xD;
&#xD;
          4. Eligible for intravenous thrombolysis with TNK-tPA;&#xD;
&#xD;
          5. Time from stroke onset to randomization within 4.25 hours;&#xD;
&#xD;
          6. Written informed consent is obtained from patients and/or their legal representatives.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. CT or MR evidence of intracranial hemorrhage;&#xD;
&#xD;
          2. Contraindications of intravenous thrombolysis;&#xD;
&#xD;
          3. Currently in pregnant or lactating or serum beta HCG test is positive on admission;&#xD;
&#xD;
          4. Contraindication to radiographic contrast agents, nickel, titanium metals or their&#xD;
             alloys;&#xD;
&#xD;
          5. Current participation in another clinical trial&#xD;
&#xD;
          6. Arterial tortuosity and/or other arterial disease that would prevent the device from&#xD;
             reaching the target vessel;&#xD;
&#xD;
          7. Patients with a preexisting neurological or psychiatric disease that would confound&#xD;
             the neurological functional evaluations;&#xD;
&#xD;
          8. Patients with occlusions in multiple vascular territories (e.g. bilateral anterior&#xD;
             circulation, or anterior/posterior circulation);&#xD;
&#xD;
          9. CT or MR evidence of mass effect or intracranial tumor (except small meningioma);&#xD;
&#xD;
         10. CT or MR angiography evidence of intracranial arteriovenous malformations or&#xD;
             aneurysms;&#xD;
&#xD;
         11. Any terminal illness with life expectancy less than 6 months;&#xD;
&#xD;
         12. Unlikely to be available for 90-day follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qingwu Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurology, Xinqiao Hospital of the Army Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raul G Nogueira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Marcus Stroke &amp; Neuroscience Center, Grady Memorial Hospital, Emory University, Atlanta, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey L Saver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurology, University of California, Los Angeles, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wenjie Zi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurology, Xinqiao Hospital of the Army Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhongming Qiu, MD</last_name>
    <phone>+8613236599269</phone>
    <email>qiuzhongmingdoctor@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fengli Li, MD</last_name>
    <phone>+8617358339092</phone>
    <email>lifengli01@yeah.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xinqiao Hospital of Army Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wenjie Zi, MD</last_name>
      <phone>+8618523033816</phone>
      <email>ziwenjie1981@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhongming Qiu</last_name>
      <phone>+8613236599269</phone>
      <email>qiuzhongmingdoctor@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Maoming Traditional Chinese Medicine Hospital</name>
      <address>
        <city>Maoming</city>
        <state>Guangdong</state>
        <zip>525000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wenguo Huang, MS</last_name>
      <phone>8613929795299</phone>
      <email>13929795299@139.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan No. 1 Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wenhua Liu, MD</last_name>
      <phone>8618871588816</phone>
      <email>leeoowh@yeah.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 904th Hospital of CPLA</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhonghua Shi, MD</last_name>
      <phone>8618921150310</phone>
      <email>18921150310@189.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shouchun Wang, MD</last_name>
      <phone>8613596060906</phone>
      <email>wangsc13@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, Yan B, Bush SJ, Thijs V, Scroop R, Simpson M, Brooks M, Asadi H, Wu TY, Shah DG, Wijeratne T, Zhao H, Alemseged F, Ng F, Bailey P, Rice H, de Villiers L, Dewey HM, Choi PMC, Brown H, Redmond K, Leggett D, Fink JN, Collecutt W, Kraemer T, Krause M, Cordato D, Field D, Ma H, O'Brien B, Clissold B, Miteff F, Clissold A, Cloud GC, Bolitho LE, Bonavia L, Bhattacharya A, Wright A, Mamun A, O'Rourke F, Worthington J, Wong AA, Levi CR, Bladin CF, Sharma G, Desmond PM, Parsons MW, Donnan GA, Davis SM; EXTEND-IA TNK Part 2 investigators. Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial. JAMA. 2020 Apr 7;323(13):1257-1265. doi: 10.1001/jama.2020.1511.</citation>
    <PMID>32078683</PMID>
  </reference>
  <reference>
    <citation>Mai LM, Oczkowski W. Tenecteplase before thrombectomy for ischemic stroke improved reperfusion compared with alteplase. Ann Intern Med. 2018 Aug 21;169(4):JC20. doi: 10.7326/ACPJC-2018-169-4-020.</citation>
    <PMID>30128510</PMID>
  </reference>
  <reference>
    <citation>Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, Yan B, Bush SJ, Dewey HM, Thijs V, Scroop R, Simpson M, Brooks M, Asadi H, Wu TY, Shah DG, Wijeratne T, Ang T, Miteff F, Levi CR, Rodrigues E, Zhao H, Salvaris P, Garcia-Esperon C, Bailey P, Rice H, de Villiers L, Brown H, Redmond K, Leggett D, Fink JN, Collecutt W, Wong AA, Muller C, Coulthard A, Mitchell K, Clouston J, Mahady K, Field D, Ma H, Phan TG, Chong W, Chandra RV, Slater LA, Krause M, Harrington TJ, Faulder KC, Steinfort BS, Bladin CF, Sharma G, Desmond PM, Parsons MW, Donnan GA, Davis SM; EXTEND-IA TNK Investigators. Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke. N Engl J Med. 2018 Apr 26;378(17):1573-1582. doi: 10.1056/NEJMoa1716405.</citation>
    <PMID>29694815</PMID>
  </reference>
  <results_reference>
    <citation>Zi W, Qiu Z, Li F, Sang H, Wu D, Luo W, Liu S, Yuan J, Song J, Shi Z, Huang W, Zhang M, Liu W, Guo Z, Qiu T, Shi Q, Zhou P, Wang L, Fu X, Liu S, Yang S, Zhang S, Zhou Z, Huang X, Wang Y, Luo J, Bai Y, Zhang M, Wu Y, Zeng G, Wan Y, Wen C, Wen H, Ling W, Chen Z, Peng M, Ai Z, Guo F, Li H, Guo J, Guan H, Wang Z, Liu Y, Pu J, Wang Z, Liu H, Chen L, Huang J, Yang G, Gong Z, Shuai J, Nogueira RG, Yang Q; DEVT Trial Investigators. Effect of Endovascular Treatment Alone vs Intravenous Alteplase Plus Endovascular Treatment on Functional Independence in Patients With Acute Ischemic Stroke: The DEVT Randomized Clinical Trial. JAMA. 2021 Jan 19;325(3):234-243. doi: 10.1001/jama.2020.23523.</citation>
    <PMID>33464335</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>January 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 2, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xinqiao Hospital of Chongqing</investigator_affiliation>
    <investigator_full_name>Zhongming Qiu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Thrombolysis</keyword>
  <keyword>Endovascular treatment</keyword>
  <keyword>Tenecteplase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenecteplase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>study data without patient information</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Related papers published 3 months later, the IPD will be shared.</ipd_time_frame>
    <ipd_access_criteria>yangqwmlys@163.com ziwenjie1981@163.com</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

